Novo Nordisk has had enough—sues Eli Lilly.

On July 21, 2026, Novo Nordisk filed a lawsuit against Eli Lilly in the U.S. District Court for the District of New Jersey, accusing Lilly of deliberately omitting critical information and misleading consumers with outdated data in its nationwide advertising campaigns for Zepbound and Mounjaro. The dispute stems from two specific Lilly advertisements: one comparing Zepbound to Wegovy, and another comparing Mounjaro to Ozempic. Comparison itself is not the issue—the problem lies in *how* the comparisons are made. According to Novo Nordisk’s complaint, Lilly’s ads pit Zepbound’s highest approved doses (10 mg / 15 mg) against Wegovy’s lower doses (1.7 mg / 2.4 mg). At first glance, Zepbound appears more effective—but Novo Nordisk points out a crucial omission: the U.S. FDA had already approved Wegovy’s new 7.2 mg dose in March 2026. In the STEP UP clinical trial, this higher dose achieved an average weight loss of approximately 19%. In other words, consumers were shown a misleading juxtaposition—comparing historical data against current, clinically validated data. A similar issue arises in the Mounjaro–Ozempic comparison: Lilly contrasts Mounjaro’s top dose (15 mg) with Ozempic’s 1 mg dose, while the FDA approved Ozempic’s 2 mg maintenance dose over four years ago. Novo Nordisk’s language is sharp: “These advertisements deliberately select outdated comparative studies—pitting their own highest approved doses against competitors’ lower doses—to create a misleading impression of superior product performance.” In fact, the FDA imposes clear requirements on direct-to-consumer drug advertising: it must fairly present both risks and benefits. If an advertisement’s comparison omits an FDA-approved higher dose—and that omission could materially affect consumers’ treatment decisions—it may constitute false or misleading promotion. The timing of this lawsuit is telling. The 7.2 mg Wegovy dose was approved just four months ago, and Novo Nordisk clearly does not want the market to underestimate its significance. The STEP UP trial data itself is strong: over 72 weeks, among 1,407 obese patients (BMI ≥30), participants achieved an average weight loss of 18.8%—one of the highest weight-loss results ever reported for a GLP-1 receptor agonist in a Phase III trial. Yet higher doses also carry greater safety risks: the most common adverse reactions in the 7.2 mg group included nausea, vomiting, constipation, abdominal pain, fatigue, headache, dizziness, hair loss, and flatulence.

Are weight-loss drug ads accused of 'gaming the system'? Two pharmaceutical giants head to court!

The clinical trials cited by both companies may be genuine—yet their advertisements may still mislead consumers. This may sound paradoxical, but it lies at the heart of Novo Nordisk’s latest lawsuit against Eli Lilly. Novo Nordisk and Eli Lilly On July 21, Novo Nordisk sued Eli Lilly in the U.S. District Court for the District of New Jersey, alleging that Lilly’s advertising for Zepbound and Mounjaro uses incomplete and outdated comparisons to claim superiority over Novo Nordisk’s Wegovy and Ozempic. In short, Novo Nordisk accuses Lilly of ‘gaming the system’—engaging in inequitable comparisons in its ad messaging. Lilly, for its part, responded that its ads are grounded in the results of the SURMOUNT-5 clinical trial and pledged to vigorously defend itself in court. At present, this remains only the plaintiff’s allegations and the defendant’s rebuttal; no court has yet ruled either party liable. Yet this legal battle raises a question relevant to all consumers: If the numbers cited in an advertisement are true, does that automatically mean the ad is not deceptive? I. What, exactly, is Novo Nordisk challenging? The controversy does not center primarily on whether the clinical trials exist—but rather on whether the *comparative benchmarks* used are fair and complete. Per Novo Nordisk’s argument, Lilly’s ads compare its own drugs’ higher approved doses against lower doses of Novo Nordisk’s products—without adequately reflecting that Wegovy has since received FDA approval for a significantly higher dose. Fairness and completeness of comparative benchmarks Novo Nordisk contends that if no head-to-head trial has been conducted using the *highest approved doses*, then advertising that prominently displays numerical results to foster the impression that “Lilly’s drug is clearly superior” may indeed be misleading. Lilly’s position, conversely, is that its ads faithfully represent an already-completed head-to-head clinical trial—and that Novo Nordisk cannot retroactively invalidate those trial results simply because it later obtained approval for a new dose. What the two companies are truly contesting goes beyond any single number: it is about how companies should communicate evolving scientific evidence to consumers. II. If the data is real, why might it still be illegal? False advertising encompasses more than outright fabrication. Every figure in an advertisement may have a legitimate source—yet if the ad deliberately omits key contextual conditions, engages in selective comparisons, or conflates results from non-comparable studies, it can still lead ordinary consumers to erroneous conclusions. For example, a company may state that its product achieves average efficacy A, while a competitor’s achieves B—yet fail to conspicuously disclose that: • The doses used differed; • The study durations varied; • The participant eligibility criteria were not aligned; • The results originated from separate, non-head-to-head trials; or • The competitor has since launched a newly FDA-approved dose. Each individual number may be accurate—but when combined, they may generate an unwarranted, overly definitive conclusion. Legal scrutiny of advertising does not stop at mechanical verification of numerical accuracy. Courts also examine the ad’s overall presentation, stated conditions of use, omissions of material information, and—critically—the likely interpretation by an ordinary, reasonable consumer.

US Judge Won't Block Eli Lilly Ads for Weight-Loss Drugs, Rules Against Novo Nordisk

23 hours ago

A US judge denied Novo Nordisk's motion to block Eli Lilly's advertising for weight-loss drugs, finding claims of irreparable harm inadequate. The decision affects competition in the obesity drug market, projected to surpass $100 billion by 2030.

reuters

2026-02-03

Feb. 3 Business Watch: Catalysis start-ups raise money; Lilly strikes deals with 2 biotech firms

2026-03-31

Eli Lilly to Acquire Narcolepsy Drug Developer for $6.3 Billion

2026-04-29

Eli Lilly Investors Eager for Foundayo Insight After Early Launch Data

2026-04-30

Lilly lifts profit forecast as surging demand for weight-loss drugs offsets pricing pressure

2026-04-30

US Premarket Movers for April 30, 2026